APOM and chronic kidney disease: Further translational and clinical studies will be required to determine whether Dapa or other SGLT2i can preserve ApoM levels in disease conditions of significant renal injury.PerspectivesCOMPETENCY IN MEDICAL KNOWLEDGE: SGLT2is improve cardiorenal outcomes in patients with HF and chronic kidney disease.